Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2023
Being more strategic and coordinated when we collaborate
6 December 2023 - Like other health entities, PHARMAC is busy working on strategies to meet the requirements of the ...
Posted by Michael Wonder on 23 Aug 2023
Updates to the Health Technology Assessment Policy and Methods Review including consultation 1 responses published
23 August 2023 - Responses to the first public consultation for the HTA Review (Consultation 1) have now been published ...
Posted by Michael Wonder on 09 Jun 2023
PHARMAC breast cancer cost saving proposal welcome but ignores patients facing “dead-end”
8 June 2023 - Breast Cancer Foundation NZ is urging PHARMAC to widen access to an already funded treatment for ...
Posted by Michael Wonder on 08 Jun 2023
Proposal to widen access to intravenous trastuzumab and change the funded brand
8 June 2023 - The proposal would also give more New Zealanders funded access to intravenous trastuzumab. ...
Posted by Michael Wonder on 29 May 2023
Consultation for various vaccine supply agreements
29 May 2023 - PHARMAC is consulting on potential new supply agreements for multiple vaccines listed in the National Immunisation Schedule. ...
Posted by Michael Wonder on 12 May 2023
Public Consultation: draft 2023-24 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP
12 May 2023 - Consultation on the draft 2023-24 Cost Recovery Implementation Statement (CRIS) for listing medicines on the Pharmaceutical ...
Posted by Michael Wonder on 18 Jan 2023
PHARMAC seeking feedback on funding a second spinal muscular atrophy treatment
19 January 2023 - PHARMAC is initiating a consultation today, seeking feedback on a proposal to fund of risdiplam (Evrysdi) for ...
Posted by Michael Wonder on 27 Sep 2022
PHARMAC seeking feedback on nusinersen sodium and adrenaline auto-injectors funding
28 September 2022 - PHARMAC has initiated two consultations today, seeking feedback on the funding of two different medicines that we've ...
Posted by Michael Wonder on 19 Sep 2022
PHARMAC considering multiple new treatments from Takeda
19 September 2022 - Pharmac has initiated consultation today on a provisional bundle deal with Takeda to fund vedolizumab for people ...
Posted by Michael Wonder on 14 Jun 2022
PHARMAC seeks views on access criteria for COVID-19 treatments
14 June 2022 - PHARMAC is seeking feedback on access criteria for two new COVID-19 treatments – tixagevimab with cilgavimab ...
Posted by Michael Wonder on 07 Apr 2022
CADTH launches consultations on proposals to enhance drug review processes
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
Posted by Michael Wonder on 16 Feb 2022
PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments
16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient ...
Posted by Michael Wonder on 14 Feb 2022
PHARMAC proposing to widen access to funded medicines
14 February 2022 - PHARMAC has issued a consultation today on proposals to widen access to two medicines, rituximab and zoledronic ...
Posted by Michael Wonder on 02 Feb 2022
Review of the National Medicines Policy – consultation on the draft closes 16 February 2022
2 February 2022 - Since August 2021, the Committee has heard from nearly 200 stakeholders through bilateral interviews and virtual group ...
Posted by Michael Wonder on 22 Dec 2021
PHARMAC publishes experts’ advice and seeks views on patient access criteria for COVID-19 treatments
22 December 2021 - PHARMAC is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback ...